HIV-induced hnrnp sumoylation in the splicing of viral and host mrnas

Active Grant Awarded

Award ID
K22AI197912
Recipient
Awarding agency
Obligated
$162,000

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 9% complete
Place of performance
Sioux Falls, SD 57197, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Augustana University Association, doing business as Augustana University, $162,000 on September 17, 2026, under Grant K22AI197912. The award falls under the Allergy and Infectious Diseases Research program (CFDA 93.855), which supports biomedical research and research training in infectious diseases and related areas.

The funded work is a K22 project to characterize how HIV-driven SUMOylation of heterogeneous nuclear ribonucleoproteins (hnRNPs) regulates alternative splicing of viral and host mRNAs in HIV-infected cells, with a focus on HNRNPA2B1 and HNRNPA3. The applicant's mass spectrometry-based proteomics uncovered widespread SUMO modification of hnRNPs during HIV-1 infection, and the project tests whether this modification remodels splicing. The obligated amount is $162,000. The period of performance runs from the September 17, 2026 award date to an ultimate completion date of August 31, 2028. Place of performance is Sioux Falls, SD 57197, USA.

Description

Abstract
HIV is an obstinate worldwide health issue. Existing drugs cannot target the HIV latent reservoir and must be taken consistently to prevent viral rebound and immune destruction. Even on these drugs, HIV-infected people are at an elevated risk of multiple malignancies and other chronic conditions. The molecular events enabling HIV replication therefore remain a valuable area of study. Alternative splicing of HIV-1 viral mrnas is critical for HIV replication. Splicing greatly expands the coding capacity of the small viral genome and is necessary for the expression of most HIV-1 viral proteins. To splice its rnas, HIV-1 hijacks the host cell's alternative splicing machinery. HIV-1 is well known to utilize post-translational modifications to "RE-wire" essential host cellular machinery into supporting HIV replication. However, how these virally-driven modifications regulate the alternative splicing pathway is an intriguing, poorly defined area. Using mass spectrometry (MS)-based proteomics, the applicant recently uncovered an exciting, unexplored mechanism potentially regulating alternative splicing in HIV-infected cells: infection with HIV-1 led to the dramatic, widespread post-translational modification of numerous heterogeneous nuclear ribonucleoproteins (HNRNPS) with small ubiquitin-like modifiers (SUMOS). HNRNPS are RNA-binding proteins known to regulate multiple stages of RNA metabolism, including the alternative splicing of both HIV-1 viral mrnas and mammalian mrnas. In settings outside of HIV infection, sumo-modification has been shown to regulate the RNA-binding and splicing activity of these HNRNPS. These findings suggest that HIV-driven hnrnp sumoylation may provide a concerted mechanism to remodel alternative splicing in HIV-infected cells. This K22 proposal will characterize this mechanism with a focus on HNRNPA2B1 and HNRNPA3, two HIV-driven sumo targets shown by others and US to mediate HIV-1 mrna splicing. We will employ a combination of biochemical and cutting-edge transcriptomic approaches to dissect the simultaneous effects of HIV-driven HNRNPA2B1 and HNRNPA3 sumoylation on the alternative splicing of (1) viral mrnas and (2) host cellular mrnas. As aberrantly spliced host cellular transcripts may influence the proliferation or survival of HIV- infected cells during the establishment of latency, single-cell transcriptomics will ultimately be used to dissect the effect of HIV-driven hnrnp sumoylation on the clonal expansion of HIV-infected CD4+ T cells. These studies will broaden our knowledge of the strategies used by HIV-1 to exploit an essential host cellular pathway, aiding in the design of novel therapeutics to prevent this process.

Quick answers

Who received award K22AI197912?

K22AI197912 was awarded to Augustana University Association by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 17, 2026.

How much is award K22AI197912 worth?

$162,000 has been obligated on K22AI197912.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award